Key facts
- It has raised $1.8M; the latest was Grant ($640K) in May 2025.
- Notable investors include Mercia Ventures, Development Bank of Wales, Business Wales Accelerated Growth Programme, Health Innovation Oxford & Thames Valley, ICURe — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for CanSense
- ·The full record, as it builds
Funding rounds
No funding rounds for CanSense are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CanSense
Developer of non-invasive blood test technology designed for the early detection of bowel cancer. The company's solution enables primary care providers to screen for colorectal cancer without invasive procedures, enabling healthcare professionals to reduce mortality rates and minimize unnecessary colonoscopies.
- Sector
- Healthcare
- HQ
- Swansea, United Kingdom
- Founded
- 2018
- Employees
- 18
- Website
- cansenseltd.com/
- Ownership
- Privately Held (backing)
CanSense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CanSense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CanSense in its N-PORT filings yet. We sweep new filings monthly.